Acceleron Pharma Inc. (NASDAQ:XLRN) has been given a $51.00 price objective by Credit Suisse Group in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective would suggest a potential upside of 44.31% from the company’s current price.

A number of other equities research analysts have also recently commented on XLRN. Piper Jaffray Companies reiterated a “buy” rating and set a $40.00 target price on shares of Acceleron Pharma in a report on Friday, July 28th. BidaskClub cut Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Citigroup Inc. raised their price objective on Acceleron Pharma to $44.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Zacks Investment Research cut Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, ValuEngine upgraded Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Acceleron Pharma currently has an average rating of “Buy” and an average price target of $44.88.

Shares of Acceleron Pharma (NASDAQ XLRN) opened at $35.34 on Tuesday. Acceleron Pharma has a fifty-two week low of $23.07 and a fifty-two week high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. Acceleron Pharma’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.55) EPS. analysts predict that Acceleron Pharma will post -2.67 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/acceleron-pharma-inc-xlrn-pt-set-at-51-00-by-credit-suisse-group/1706785.html.

In other Acceleron Pharma news, major shareholder Corp /De/ Celgene purchased 745,592 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were bought at an average price of $37.00 per share, with a total value of $27,586,904.00. Following the completion of the acquisition, the insider now owns 6,118,479 shares in the company, valued at approximately $226,383,723. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP John D. Quisel sold 5,113 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total value of $196,441.46. Following the sale, the senior vice president now directly owns 57,918 shares in the company, valued at approximately $2,225,209.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,513 shares of company stock valued at $2,055,485. 3.90% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the stock. Quantbot Technologies LP raised its holdings in Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Acceleron Pharma by 969.9% during the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 3,288 shares in the last quarter. NJ State Employees Deferred Compensation Plan bought a new stake in Acceleron Pharma during the second quarter worth approximately $213,000. Oppenheimer & Co. Inc. bought a new stake in Acceleron Pharma during the third quarter worth approximately $225,000. Finally, Tudor Investment Corp ET AL raised its holdings in Acceleron Pharma by 8.5% during the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 716 shares in the last quarter. 75.85% of the stock is currently owned by hedge funds and other institutional investors.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.